drug

peramivir

1 story · latest Nov 4, 2026

Follow peramivir. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.

Follow free for 14 daysNo card.

Status: FDA approved Dec 2014 · NDA206426
Brand: Rapivab

Relationships

Developed by Biocryst Pharmaceuticals Inc

Timeline

BioCryst reports Q3 2026 results, ORLADEYO pellet approval, and raises revenue guidance

Nov 4Quarterly updateberotralstat Biocryst Pharmaceuticals Inc

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.